| 1.85 0.17 (10.12%) | 03-05 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.16 |
1-year : | 2.52 |
| Resists | First : | 1.85 |
Second : | 2.16 |
| Pivot price | 1.57 |
|||
| Supports | First : | 1.54 |
Second : | 1.36 |
| MAs | MA(5) : | 1.7 |
MA(20) : | 1.57 |
| MA(100) : | 1.56 |
MA(250) : | 0.99 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 96.1 |
D(3) : | 93.5 |
| RSI | RSI(14): 65.9 |
|||
| 52-week | High : | 2 | Low : | 0.24 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ OVID ] has closed Bollinger Bands are 14.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.85 - 1.86 | 1.86 - 1.87 |
| Low: | 1.63 - 1.64 | 1.64 - 1.65 |
| Close: | 1.83 - 1.85 | 1.85 - 1.86 |
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Wed, 04 Mar 2026
OVID Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Wed, 04 Mar 2026
OVID: OV329 and OV4071 advance in CNS disorders, with major clinical data expected within 18 months - TradingView
Wed, 04 Mar 2026
OVID: Two CNS programs—OV329 for epilepsy and OV4071 for psychosis—advance with pivotal data ahead - TradingView
Tue, 03 Mar 2026
OVID PE Ratio & Valuation, Is OVID Overvalued - Intellectia AI
Sun, 01 Mar 2026
Ovid Therapeutics (NASDAQ:OVID) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Wed, 25 Feb 2026
Ovid Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 71 (M) |
| Held by Insiders | 5.445e+007 (%) |
| Held by Institutions | 9.8 (%) |
| Shares Short | 4,380 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.865e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -9 % |
| Return on Assets (ttm) | 487.1 % |
| Return on Equity (ttm) | -29.4 % |
| Qtrly Rev. Growth | 6.61e+006 % |
| Gross Profit (p.s.) | -91.16 |
| Sales Per Share | -231.01 |
| EBITDA (p.s.) | 2.54231e+007 |
| Qtrly Earnings Growth | -0.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -38 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.76 |
| Dividend | 0 |
| Forward Dividend | 4.84e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|